Clinical Trial Update: Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of two fixed doses of paliperidone extended-release tablets in adults with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone ER (Invega) (paliperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED